TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26852502

Group type: EXPERIMENTAL
Intervention: Local ozone therapy
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Combination of local and general ozone therapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Basic therapy alone
Number of subjects: 102
Study: 23189931

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Supreme
Number of subjects: 170
Study: 21514114

Group type: EXPERIMENTAL
Intervention: Fibrin sealant with clamps opened at 120 seconds (FS-120; N = 24)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Manual compression with surgical gauze pads (control; N = 23)
Number of subjects: 73
Study: 18496106

Group type: EXPERIMENTAL
Intervention: Standardized Psychoeducation (SE)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Telephone Counseling (TC)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Standardized Psychoeducation plus Telephone Counseling (SE + TC)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Disease Management (DM)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 249
Study: 16204324

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 72

Group type: COMPARATOR
Intervention: Balanced mixture (control)
Number of subjects: 72
Study: 12952263

Group type: EXPERIMENTAL
Intervention: Platelet-activating factor (PAF)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Lyso-PAF (L-PAF)
Number of subjects: 9
Study: 10649811

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE), 0.625 mg/d
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE), 1.25 mg/d
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Esterified estrogens, 0.625 mg + methyltestosterone, 1.25 mg/d
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Esterified estrogens, 1.25 mg + methyltestosterone, 2.5 mg/d
Number of subjects: 311

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 311
Study: 8886339

Group type: EXPERIMENTAL
Intervention: Chocolate bar supplementation before exercise
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1986661

Group type: EXPERIMENTAL
Intervention: Flumazenil (up to 1 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6405056

Group type: EXPERIMENTAL
Intervention: Transurethral resection followed by bladder instillations of thiotepa or VM‐26 (teniposide) for 1 year
Number of subjects: 308

Group type: COMPARATOR
Intervention: Transurethral resection alone
Number of subjects: 308
Study: 29305927

Group type: EXPERIMENTAL
Intervention: Hypothermia (33.0 °C)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Normothermia (36.8 °C)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: VABS-II scores at 12 months
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Cognitive testing at 12 months
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: VABS-II composite scores
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Correlation of 3 and 12-month scores
Number of subjects: 269
Study: 27514259

Group type: EXPERIMENTAL
Intervention: Health education intervention for 6 months through bulletin board, promotion materials, expert lecture, Q&A session, and other educational events.
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Health education intervention for 6 months.
Number of subjects: 990

Group type: COMPARATOR
Intervention: Control group (no health education).
Number of subjects: 990
Study: 25040613

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 50 mcg once-daily
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 mcg twice-daily
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study: 22395779

Group type: EXPERIMENTAL
Intervention: Aminophylline (75 mg intravenous)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 20105234

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left DLPFC and cathodal tDCS over the right DLPFC
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Right anodal/left cathodal stimulation
Number of subjects: 28
Study: 18192544

Group type: EXPERIMENTAL
Intervention: AIR inhaled insulin (12 units)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Salbutamol plus AIR insulin (moderate asthma group only)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Subcutaneous insulin lispro (12 units)
Number of subjects: 39
Study: 16418159

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH)
Number of subjects: 1323

Group type: COMPARATOR
Intervention: atomoxetine
Number of subjects: 1323
Study: 12851613

Group type: EXPERIMENTAL
Intervention: roxifiban
Number of subjects: 31

Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 31
Study: 10323788

Group type: EXPERIMENTAL
Intervention: Used fat meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unused fat meal
Number of subjects: 12
Study: 8611060

Group type: EXPERIMENTAL
Intervention: Imipramine treatment combined with weekly relapse prevention psychotherapy
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Imipramine treatment
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 1934862

Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Yogurt
Number of subjects: 7

Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg) with 300 ml water
Number of subjects: 7
Study: 7073026

Group type: EXPERIMENTAL
Intervention: Isoetharine (1% solution)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Isoproterenol (0.5% solution)
Number of subjects: 18
Study: 6734291

Group type: EXPERIMENTAL
Intervention: Dual screen with annual chest x-ray examination and four monthly sputum cytology evaluation
Number of subjects: 10040

Group type: COMPARATOR
Intervention: Annual chest x-ray examinations only
Number of subjects: 10040
Study: 29283207

Group type: EXPERIMENTAL
Intervention: Submerged healing group (n=14)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Transmucosal healing group (n=14)
Number of subjects: 28
Study: 27484701

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg loading dose infused over 10 min followed by a constant infusion of 0.5 μg/kg/h) added to propofol-remifentanil regimen (DP adjusted group)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine added to propofol-remifentanil regimen without adjustment (DP unadjusted group)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Propofol-remifentanil regimen (Propofol group)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg loading dose infused over 10 min followed by a constant infusion of 0.5 μg/kg/h) added to propofol-remifentanil regimen (DP unadjusted group)
Number of subjects: 71
Study: 25522403

Group type: EXPERIMENTAL
Intervention: Silexan (160 mg daily for a minimum of 8 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Silexan
Number of subjects: 17
Study: 22460728

Group type: EXPERIMENTAL
Intervention: Chronic PPI use
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (never used antacid medications)
Number of subjects: 30
Study: 20394460

Group type: EXPERIMENTAL
Intervention: Pharmacist management of diabetes (including medication management, patient education, and disease control)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Usual medical care (control group management included registries and targeted patient outreach)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Pharmacist management of diabetes (specifically for nonwhite patients)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Pharmacist management of diabetes (specifically for male patients)
Number of subjects: 103
Study: 17498718

Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Polyphenols-stripped red wine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ethanol-water solution
Number of subjects: 9

Group type: COMPARATOR
Intervention: Water
Number of subjects: 9
Study: 15976148

Group type: EXPERIMENTAL
Intervention: two servings of low energy-dense soup
Number of subjects: 200

Group type: COMPARATOR
Intervention: comparison group (no special food)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: two servings of high energy-dense snack foods
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: one serving of low energy-dense soup
Number of subjects: 200
Study: 12055563

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 10663352

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 120
Study: 8739175

Group type: EXPERIMENTAL
Intervention: Braun/Oral-B Plak Control (D7)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sonicare (S)
Number of subjects: 35
Study: 1756202

Group type: EXPERIMENTAL
Intervention: m-CPP (0.5 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine (480 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7042732

Group type: EXPERIMENTAL
Intervention: Baclofen 5 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Baclofen 10 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Baclofen 20 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30428059

Group type: EXPERIMENTAL
Intervention: Self-Mutual-Group model (SMG) intervention for 7 months
Number of subjects: 350

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 350
Study: 28193257

Group type: EXPERIMENTAL
Intervention: Prednisolone 1 mg/kg/day to a maximum of 50 mg/day for 10 days
Number of subjects: 540

Group type: COMPARATOR
Intervention: Placebo (taste matched) for 10 days
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 540
Study: 25389300

Group type: EXPERIMENTAL
Intervention: Brief TSP intervention
Number of subjects: 1101

Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 1101
Study: 22528813

Group type: EXPERIMENTAL
Intervention: Untreated essential hypertension
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normotensive control group
Number of subjects: 60
Study: 22027927

Group type: EXPERIMENTAL
Intervention: ATG/Dac (3 ATG, 2 Dac doses)
Number of subjects: 200

Group type: COMPARATOR
Intervention: ATG/alemtuzumab (1 dose each)
Number of subjects: 200
Study: 19928387

Group type: EXPERIMENTAL
Intervention: Intermittent bright light pulses during night shifts, wearing dark sunglasses outside, scheduled sleep episodes in darkness
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group with no interventions
Number of subjects: 39
Study: 16827637

Group type: EXPERIMENTAL
Intervention: Azithromycin-containing toothpaste (85 mg azithromycin per gram, prescribed b.i.d., 1.5 cm for 1 month)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Azithromycin-containing toothpaste
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control toothpaste
Number of subjects: 20
Study: 15018588

Group type: EXPERIMENTAL
Intervention: Cetrorelix (0.25mg daily injections or 3mg intermediate depot preparation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ganirelix (0.25mg daily injections)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GnRH antagonist multiple-dose protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GnRH antagonist single-dose protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: GnRH agonist cycles
Number of subjects: 0
Study: 11371127

Group type: EXPERIMENTAL
Intervention: GnRH analogs (leuprolide acetate) administered prior to and during polychemotherapy (PCT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No GnRH analogs (Control Group A)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No GnRH analogs (Control Group C)
Number of subjects: 21
Study: 9346996

Group type: EXPERIMENTAL
Intervention: Neonatal screening for cystic fibrosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard diagnostic methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screened group in urban center
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group in other center
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Entire CF populations in urban center
Number of subjects: 0
Study: 8192646

Group type: EXPERIMENTAL
Intervention: Composite index for treatment outcome research with social phobia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-report measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical ratings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral performance measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite index
Number of subjects: 0
Study: 3555692

Group type: EXPERIMENTAL
Intervention: Closure and proximal gastric vagotomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Simple closure
Number of subjects: 50
Study: 30217726

Group type: EXPERIMENTAL
Intervention: General endotracheal anesthesia (GEA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Monitored anesthesia care (MAC)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: General endotracheal anesthesia (GEA) and Monitored anesthesia care (MAC)
Number of subjects: 200
Study: 28053275

Group type: EXPERIMENTAL
Intervention: BVAS (Baseline Vasculitis Activity Score)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Subsequent development of malignancy
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Mucous membrane or eye involvement
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Baseline creatinine
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: CRP (C-reactive protein) increase (per 10 mg/l)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Cutaneous involvement
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Gastrointestinal involvement
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Baseline creatinine increase (per 100 µmol/l)
Number of subjects: 417
Study: 26095242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: 1000 IU/d of vitamin D3
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: 2000 IU/d of vitamin D3
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: 4000 IU/d of vitamin D3
Number of subjects: 328
Study: 23219108

Group type: EXPERIMENTAL
Intervention: Protein diet (25% of energy intake)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Carbohydrate diet (15% of energy intake)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Unsaturated fat diet (15% of energy intake)
Number of subjects: 164
Study: 21854503

Group type: EXPERIMENTAL
Intervention: SBR759 (3.0 or 4.5 g/day)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Sevelamer hydrochloride (2.4 or 4.8 g/day)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: SBR759
Number of subjects: 203
Study: 17971091

Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a (40KD) 180μg/week plus ribavirin 1000/1200 mg/day for 48 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a (40KD) plus ribavirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (patients with elevated ALT levels)
Number of subjects: 0
Study: 16947384

Group type: EXPERIMENTAL
Intervention: Abatacept (10 mg/kg by weight range)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abatacept plus biologic agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other subgroups (not receiving biologic agent)
Number of subjects: 0
Study: 12969096

Group type: EXPERIMENTAL
Intervention: Methohexital plus remifentanil (0.625 mg kg‐1 methohexital + 1 micro g kg‐1 remifentanil)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Methohexital alone (1.25 mg kg‐1)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Methohexital plus remifentanil
Number of subjects: 7

Group type: COMPARATOR
Intervention: Methohexital alone
Number of subjects: 7
Study: 11885170

Group type: EXPERIMENTAL
Intervention: HA-coated implants
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Non-HA-coated implants
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Implants mobile at uncovering
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Bone quality-4
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Implants with facial bone thickness >= 1.8 mm
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Implants that failed to integrate
Number of subjects: 3000

Group type: COMPARATOR
Intervention: HA-coated vs non-HA-coated implants
Number of subjects: 3000
Study: 9383226

Group type: EXPERIMENTAL
Intervention: Immediate administration of G-CSF (day +1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Delayed, patient-dependent G-CSF therapy (first day when ANC was below 0.5 x 10[9]/1)
Number of subjects: 70
Study: 8463731

Group type: EXPERIMENTAL
Intervention: Topical prednisolone phosphate 1.0% administered 4 times daily to the right eye
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo administered to the left eye
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Topical prednisolone phosphate 1.0%
Number of subjects: 13
Study: 3534869

Group type: EXPERIMENTAL
Intervention: Captopril once daily (100 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Captopril twice daily (50 mg)
Number of subjects: 9
Study: 30143950

Group type: EXPERIMENTAL
Intervention: PEERS® intervention (14-week parent-assisted training)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 72
Study: 29708400

Group type: EXPERIMENTAL
Intervention: Video follow-up (VF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional clinic follow-up (CF)
Number of subjects: 0
Study: 27779951

Group type: EXPERIMENTAL
Intervention: Night Vision Goggles (NVG) during flight simulation
Number of subjects: 4

Group type: COMPARATOR
Intervention: Standard helmet only (Control) during flight simulation
Number of subjects: 4
Study: 24814735

Group type: EXPERIMENTAL
Intervention: EMR with SMR access
Number of subjects: 62

Group type: COMPARATOR
Intervention: EMR without SMR access
Number of subjects: 62
Study: 22132827

Group type: EXPERIMENTAL
Intervention: Amoxicillin trihydrate-potassium clavulanate (Clavamox)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 20940176

Group type: EXPERIMENTAL
Intervention: Maternal plasma levels of PFOS (ng/mL)
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Maternal plasma levels of PFOA (ng/mL)
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Body mass index measurements
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Sex stratification
Number of subjects: 1010
Study: 18723709

Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg, max 10 mg over 5 min)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 71
Study: 15941955

Group type: EXPERIMENTAL
Intervention: PREVENT intervention (telephone-delivered intervention plus tailored materials)
Number of subjects: 1247

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: PREVENT intervention
Number of subjects: 1247
Study: 12954462

Group type: EXPERIMENTAL
Intervention: Predicted standard deviation (SD) used in sample size calculation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sample size calculation
Number of subjects: 0
Study: 10561339

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 11064

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11064
Study: 8934257

Group type: EXPERIMENTAL
Intervention: Cyclical treatment with 2 mg of oral estradiol valerate in combination with 250 micrograms of levonorgestrel for the last ten days (Cyclo Progynova)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Continuous treatment with 2 mg estradiol valerate orally in combination with a 20 micrograms per 24 hour levonorgestrel releasing intrauterine device
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 40
Study: 8320744

Group type: EXPERIMENTAL
Intervention: DDATHF 3.0 mg/m2 per week
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: DDATHF 4.5 mg/m2 per week
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: DDATHF 6.0 mg/m2 per week
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: DDATHF
Number of subjects: 33
Study: 2883003

Group type: EXPERIMENTAL
Intervention: 200 mg Epanolol-Visacor (ISA)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 100 mg Metoprolol (without ISA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30281035

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 0
Study: 27363578

Group type: EXPERIMENTAL
Intervention: Warm needling therapy (GV14 and acupuncture at EX-HN3, ST2, LI20, EX-HN8, GV23, LU7, LU5, LI4) three times a week for 4 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Oral loratadine 10 mg/day for 4 weeks
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Warm needling therapy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Oral loratadine
Number of subjects: 98
Study: 25711326

Group type: EXPERIMENTAL
Intervention: Baseline genotypic resistance testing
Number of subjects: 1946
Study: 23643139

Group type: EXPERIMENTAL
Intervention: Pancreaticojejunostomy
Number of subjects: 329

Group type: COMPARATOR
Intervention: Pancreaticogastrostomy
Number of subjects: 329
Study: 20054841

Group type: EXPERIMENTAL
Intervention: Spaced Retrieval (SR)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Montessori-based activities
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study: 18511016

Group type: EXPERIMENTAL
Intervention: 1 mg oral estradiol (oE(2))
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.05 mg transdermal estradiol (tE(2))
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy premenopausal women
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal postmenopausal women
Number of subjects: 50